Singaporean and European scientists team up

The agreement will enable scientists to apply for EMBO Short-Term and Long-Term Fellowships to work in Singapore or Europe.

Scientists in Singapore and Europe will have access to new platforms for scientific interaction and collaborative research, following a cooperation agreement between EMBO, its intergovernmental funding body, EMBC, and the government of Singapore. The agreement will allow Singapore scientists to participate in EMBO training programmes and activities. It also means that EMBO workshops and lectures can take place in Singapore. This is the first cooperation agreement of its kind between EMBO, EMBC and Singapore.

 “EMBO promotes and encourages the development of the life sciences within Europe and beyond. We welcome the opportunity to ensure the mobility of scientists between Singapore and Europe and we look forward to the scientific collaboration that this agreement will bring,” said EMBO Director Maria Leptin.

Chairman of Singapore’s Agency for Science, Technology and Research (A*STAR), Mr Lim Chuan Poh, said that Singapore shared the same vision. “We are confident that this agreement will spur international collaborations in world-class scientific research, which will pave the way for new biomedical discoveries and global healthcare solutions.”

A*STAR represented Singapore in negotiations. The agreement brings together major players in Singapore’s biomedical research scene, namely A*STAR, the National University of Singapore (NUS) and the Nanyang Technological University (NTU).

New opportunities for scientific interaction
Under the agreement, scientists can apply for EMBO Short-Term and Long-Term Fellowships to work in Singapore or Europe. Scientists from Singapore can apply to the EMBO Young Investigator Programme, which provides outstanding young scientists with financial, academic and practical support to start up their first independent research laboratories.

Singapore and EMBO will also cooperate in the organisation of an EMBO Workshop in Singapore, allowing scientists from different fields to pursue cross-disciplinary collaborations. The workshop organizers from Singapore and Europe can apply for the support of an EMBO Member or Young Investigator as plenary lecturer at their event. Other conferences in Singapore can also apply for the support of an EMBO Member or Young Investigator as speaker, according to an A*STAR report.

The cooperation agreement will run for three years.

Singapore and EMBO: a growing relationship
The cooperation agreement builds on a growing series of exchanges between Singapore and scientists associated with EMBO. Key EMBO Members based in Singapore include NTU President Professor Bertil Andersson; A*STAR Chief Scientist, Professor Sir David Lane; Chairman of A*STAR’s Biomedical Research Council, Professor Sir George Radda; and NTU Professor of Biological Sciences and Chair of EMBO Council, Daniela Rhodes. Since 2005, there have been eight EMBO-funded events in Singapore, including a 2011 Plenary Lecture. In 2009, 12 EMBO Gold Medalists presented their work and held discussions with 300 researchers based in Singapore on a range of topics in developmental, cell and molecular biology.

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.